demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
metastatic/advanced RCC (mRCC) - 2nd line (L2)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
atezolizumab plus cabozantinib CONTACT-03